Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00770328 · ClinicalTrials.gov registry record · Phase 4

The Effects of Pentoxifylline on PAI-1 in an Obese Population

A Phase 4 study of Obesity, sponsored by Vanderbilt University.

Completed
Registry status
Phase 4
Development phase
37
Enrollment target
1
Study location

NCT00770328: Completed Phase 4 study of Obesity, sponsored by Vanderbilt University.

NCT00770328 is a Phase 4 study of Obesity that has completed, run by Vanderbilt University. The registered enrollment target is 37 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00770328, a Phase 4 study of Obesity, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Phase 4
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal models. This study tests the hypothesis that pentoxifylline will lower PAI-1 levels in human subjects.

Conditions Studied

Obesity

Interventions

  • DRUG Placebo
  • DRUG Pentoxifylline

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2003-05
Est. Completion 2009-06
Phase Phase 4
Vanderbilt University

430 total trials

What the finished NCT00770328 record still lists

NCT00770328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00770328 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00770328 about?

NCT00770328 is a clinical study titled "The Effects of Pentoxifylline on PAI-1 in an Obese Population". PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal models. This study tests the hypothesi...

What is the current status of trial NCT00770328?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2003-05. Estimated completion is 2009-06.

What conditions does trial NCT00770328 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT00770328?

The interventions under investigation include: Placebo (DRUG), Pentoxifylline (DRUG).

Who is sponsoring clinical trial NCT00770328?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00770328 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00770328's enrollment target sits among peer trials

37 816th of 1053 higher than 235 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00770328, the US trial registry maintained by the National Library of Medicine. NCT00770328 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.